Aptevo Therapeutics Inc. (NASDAQ:APVO) and Novus Therapeutics Inc. (NASDAQ:NVUS) are two firms in the Biotechnology that compete against each other. Below is a comparison of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptevo Therapeutics Inc.	19.54M	1.94	49.36M	-2.21	0.00
Novus Therapeutics Inc.	N/A	0.00	11.60M	-1.37	0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Aptevo Therapeutics Inc. and Novus Therapeutics Inc.

Profitability

Table 2 shows us Aptevo Therapeutics Inc. and Novus Therapeutics Inc.’s return on equity, return on assets and net margins.

	Net Margins	Return on Equity	Return on Assets
Aptevo Therapeutics Inc.	-252.61%	-78.8%	-51.1%
Novus Therapeutics Inc.	0.00%	-55.5%	-51.7%

Liquidity

Aptevo Therapeutics Inc.’s Current Ratio and Quick Ratio are 3.9 and 3.7 respectively. The Current Ratio and Quick Ratio of its competitor Novus Therapeutics Inc. are 10.7 and 10.7 respectively. Novus Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to Aptevo Therapeutics Inc.

Institutional and Insider Ownership

The shares of both Aptevo Therapeutics Inc. and Novus Therapeutics Inc. are owned by institutional investors at 32.9% and 52.9% respectively. Insiders owned roughly 0.6% of Aptevo Therapeutics Inc.’s shares. Competitively, insiders own roughly 0.8% of Novus Therapeutics Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Aptevo Therapeutics Inc.	-10.87%	-40.92%	-60.5%	-59.88%	-45.62%	-51.65%
Novus Therapeutics Inc.	-20.46%	-33.01%	-39.07%	-56.67%	-36.7%	-32.02%

For the past year Aptevo Therapeutics Inc. was more bearish than Novus Therapeutics Inc.

Summary

Novus Therapeutics Inc. beats Aptevo Therapeutics Inc. on 6 of the 9 factors.

Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn. The companyÂ’s marketed products also comprise HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B; and VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals. Its investigational stage product candidates include MOR209/ES414, a bispecific immunotherapeutic protein that is in Phase I clinical trial for metastatic castration-resistant prostate cancer; ES210, a bispecific protein therapeutic that is in pre-clinical development stage for inflammatory bowel diseases; otlertuzumab, a monospecific protein therapeutic that is in Phase II clinical trial for chronic lymphocytic leukemia; ROR1, a bispecific immunotherapeutic protein that is in preclinical development; APVO436, a bispecific protein therapeutic, which is in pre-clinical development; and other therapeutic protein product candidates for cancer. The company was incorporated in 2016 and is based in Seattle, Washington.

Novus Therapeutics, Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of ear, nose, and throat products. Its lead product is a nasally-administered combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD) conditions. The company also has a foam-based drug delivery technology platform (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. It is developing a foam-based combination drug-product to the external ear canal that is an improved treatment option for acute otitis externa. The company is headquartered in Irvine, California.